Yasumatsu R, et al. - A sum of 41 cases with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) to assess the utility of neutrophil-to-lymphocyte ratio (NLR) kinetics to predict the anticancer impact of nivolumab using pretreatment blood test results. They noticed higher posttreatment NLR as compared to the pretreatment value 76% of subjects with progressive disease within the first 3 months. But, among stable disease or partial response during the follow-up period, they recorded lower posttreatment NLR than the pretreatment value in 91% of cases. Consequently, they suggested monitoring of NLR as it might help in pre-confirming the treatment failure during nivolumab monotherapy.